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BiosensorsAdenosine is a signaling molecule and downstream product of ATP that acts as a neuromodulator. Adenosine
regulates physiological processes, such as neurotransmission and blood ﬂow, on a time scale of minutes to
hours. Recent developments in electrochemical techniques, including fast-scan cyclic voltammetry (FSCV),
have allowed direct detection of adenosine with sub-second temporal resolution. FSCV studies have revealed a
novelmode of rapid signaling that lasts only a few seconds. This rapid release of adenosine can be evoked by elec-
trical or mechanical stimulations or it can be observed spontaneously without stimulation. Adenosine signaling
on this time scale is activity dependent; however, the mode of release is not fully understood. Rapid adenosine
releasemodulates oxygen levels and evoked dopamine release, indicating that adenosinemay have a rapidmod-
ulatory role. In this review, we outline how FSCV can be used to detect adenosine release, compare FSCV with
other techniques used to measure adenosine, and present an overview of adenosine signaling that has been
characterized using FSCV. These studies point to a rapid mode of adenosine modulation, whose mechanism
and function will continue to be characterized in the future.
© 2015 Nguyen and Venton. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
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y/4.0/).1. Introduction
Adenosine signaling was ﬁrst discovered in 1929 and it regulates
numerous physiological processes at the cellular level. Adenosinetwork of Computational and Structural Biotechnology. This is an open access article under
Fig. 1. Detection of adenosine with FSCV. A) Applied potential waveform. The electrode is
held at−0.40 V, ramped up to a switching potential of 1.45 V and back at 400 V/s. The
scan is repeated every 100ms. B) The cyclic voltammogram (CV) is large due to the back-
ground charging current in the buffer (black dotted line) and the addition of 1.0 μMaden-
osine (red line). C) Subtracting out the background yields a background-subtracted CV of
adenosine oxidation. The primary oxidation is observed at 1.4 V and the secondary oxida-
tion at 1.0 V. The primary peak current is proportional to the concentration of adenosine
detected at the electrode. D) False color plot of multiple background subtracted CVs. The
x-axis is time, the y-axis is applied potential, and the color is current. This plot depicts
an in vitro calibration experiment where the buffer is ﬂowed by the electrode for 5 s,
then 1.0 μM adenosine is ﬂowed by for 5 s and ﬁnally buffer is ﬂowed again. The large
green oval in the center of the plot is the primary oxidation peak and the smaller green
oval below is the secondary oxidation peak.
Data adapted from Nguyen et al. [29].
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neurotransmission [5]. Adenosine is considered a neuromodulator,
since it acts over extended periods of time and over a diffuse area [6].
Adenosine is also neuroprotective and released during events such as
stroke and ischemia [7]. A breakdown product of ATP, adenosine can
build up due to energy consumption and metabolic processes [6]. The
effects of adenosine are complicated because it can be both excitatory
and inhibitory. Pharmacological studies have demonstrated that A1
receptors primarily mediate inhibitory effects while A2a receptors facil-
itate excitatory effects of adenosine [8]. For example, the A1 adenosine
receptor modulated preconditioning against anoxia [9] and A2a recep-
tors modulated rapid eye movements and breathing [10]. Both A1 and
A2a receptors regulated glutamate-induced depression of excitatory
post synaptic potentials (EPSPs) [11]. Pharmacological studies can re-
veal which receptors adenosine acts at but do not give any information
about the levels of adenosine that are available for signaling.
Techniques that directly measure adenosine release can be used to
understand the amount of adenosine in the extracellular space. Early
studies used radiometric labeling of adenosine coupled with HPLC anal-
ysis to examine the breakdown of ATP to adenosine [12]. Microdialysis
coupled to HPLC was also used to measure adenosine increases [13].
These methods measured adenosine on the minute time scale but
recently, electrochemical techniques have been developed that allow
direct measurements on the second and even sub-second time scale.
Fast, discrete release of adenosine has been characterized, which
shows that adenosine exhibits characteristics of a neurotransmitter, as
it is tightly regulated and cleared on a fast time scale. However, while
adenosine has recently been reported in vesicles [14], there is currently
no direct evidence that adenosine is released through exocytosis [15].
Enzyme biosensors speciﬁc for adenosine [16] have a response time of
2 s and were used to show that increases in adenosine occur within
2 min following ischemic events [17]. Fast-scan cyclic voltammetry
(FSCV) at carbon-ﬁber microelectrodes directly measures adenosine
on a sub-second time scale [18,19], with a sampling rate of 10 times
per second. FSCV has been used to study stimulated release in vivo
[20,21] and in brain slices [22–24]. These studies revealed that adeno-
sine can be released and cleared in only a few seconds. However, the
function of rapid adenosine release is still being elucidated. FSCV is the
fastest method currently available for measuring adenosine changes
and combined with pharmacology and electrophysiology, it has the ca-
pability of revealing how adenosine signals on a rapid time scale. In this
review, we examine the fundamental principles of adenosine detection
by FSCV, compare it to other measurement techniques, and highlight
the biological applications and possible future studies that rapid mea-
surements with FSCV may enable.
2. Adenosine Detection With Fast-scan Cyclic Voltammetry (FSCV)
FSCV is an electrochemical technique that was developed to mea-
sure changes in electroactive neurotransmitters, especially dopamine
[25]. To measure adenosine with FSCV, a triangular potential is applied
scanning from−0.40 V to 1.45 or 1.50 V and back versus a Ag/AgCl ref-
erence electrode at 400 V/s (Fig. 1A). The scan takes less than 10ms and
scans are repeated at 100 ms, which is the temporal resolution of the
technique. The working electrode is a carbon-ﬁber microelectrode
with a 7 μmdiameter, which allowsmeasurements in discrete brain re-
gions. The fast scan rates cause a large background charging current
(Fig. 1B) due to double layer charging at the electrode. The background
current is stable over time and can be subtracted out from the signal [26,
27]. The result of subtracting the background current of the dashed line
(buffer only) and the red line (buffer and adenosine) in Fig. 1B is a
characteristic cyclic voltammogram for 1 μM adenosine (Fig. 1C).
Adenosine is an electroactive molecule that can undergo a series of
three, two-electron oxidations (Scheme 1) [28]. The initial oxidation
of adenosine from product I to product II in Scheme 1 is observed at
1.4 V with FSCV. A secondary oxidation, from product II to product III,is detected at 1.0 V. The ﬁrst two oxidation steps are irreversible and
reduction peaks are not observed. The third oxidation in the scheme is
seldom observed with FSCV at our carbon-ﬁber microelectrodes. Thus,
the characteristic cyclic voltammogram (CV) for adenosine has two
oxidation peaks, with the largest peak being near the switching poten-
tial at 1.4 V (Fig. 1C) [19].
Since many CVs are collected over time, it is useful to visualize mul-
tiple voltammograms simultaneously in false color plots (Fig. 1D). A
vertical slice through the color plot at 7.5 s gives a CV of adenosine
(Fig. 1C). The primary peak appears about a half second before the sec-
ondary peak on the color plot [29]. A horizontal slice through the color
plot at 1.4 V shows how the oxidation current of adenosine changes
against potential. With an appropriate calibration value, that current
can be converted to concentration.
Traditionally, FSCV has been used to detect catecholamines such as
dopamine [30] and norepinephrine [31] but it can also detect serotonin
[32], histamine [33], and hydrogen peroxide [34]. Dopamine, serotonin,
and norepinephrine have oxidation peaks around 0.6 V and reductions
peaks between 0.2 V and−0.2 V [35,36] and the peaks do not interfere
with adenosine detection. Hydrogen peroxide has a similar oxidation
peak as adenosine at 1.2 V, but has no secondary peak, which distin-
guishes it from adenosine [34]. Histamine also has a similar oxidation
potential as adenosine, however, the secondary peak potential is
lower than that of adenosine [33].
The same electroactive adeninemoiety is present in ATP and adeno-
sine, so the electrochemical signatures of adenosine and ATP are similar.
However, interferences can be minimized and adenosine distinguished
from ATP with FSCV. Regular carbon-ﬁber microelectrodes were more
sensitive for adenosine than for ATP when the applied waveform has a
negative holdingpotential of−0.4V [19]. Electrodes coatedwithNaﬁon
and carbon nanotubes were six-fold more sensitive for adenosine than
for ATP [37]. Recently, our laboratory developed a sawhorse waveform
that helped distinguish adenosine and ATP [38]. The altered waveform
wasmore sensitive for adenosine and gave distinct signals for adenosine
over ATP; however there was still some overlap between the two mol-
ecules. To positively identify adenosine release in vivo, pharmacological
Scheme 1. Oxidation mechanism of adenosine. Adenosine undergoes a three sequential, 2-electron oxidations. The ﬁrst two oxidations are observed using FSCV and are irreversible. R is a
ribose unit.
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veriﬁed by independent techniques, such as biosensors [39]. These ap-
proaches were similar to those used to distinguish dopamine from
other catecholamines [40] and veriﬁed that adenosine was monitored
by FSCV.
3. Comparison of Adenosine Detection With FSCV and
Other Methods
3.1. Comparison of Microdialysis and FSCV
Microdialysis is one of the most general techniques for monitoring
neurochemical changes. A microdialysis probe is inserted into the
brain and artiﬁcial cerebral spinal ﬂuid is pumped through the probe.
The probe is semi-permeable allowing molecules to diffuse and be
collected in the dialysate. The aliquot is usually analyzed with HPLC
and one advantage is that many species can be measured from the
same sample [41]. For example, adenosine was quantiﬁed and separat-
ed fromhypoxanthine anduric acid [42]. The limit of detection for aden-
osine was as low as 5 nM using microdialysis [43]. Microdialysis
monitoring has revealed that adenosine is released during ischemia
and built up in 15 min [44]. Microdialysis samples were collected for 5
to 10min, so the time scale of themeasurement is slower than FSCV.Mi-
crodialysis is good for studying slower changes in basal levels of adeno-
sine while FSCV is better at detecting rapid ﬂuctuations in extracellular
adenosine.
3.2. Comparison of Electrophysiology and FSCV
Electrophysiology studies monitor the ﬁring of neurons and can be
used to examine the effects of adenosine release. For example, adeno-
sine depressed EPSPs and thus decreased post-synaptic neurotransmis-
sion [45]. Electrophysiology studies found that endogenous adenosine
release in hippocampal slices was activity dependent and acted via A1
receptors [46].
Electrophysiology studies look at downstream effects of adenosine
on cell ﬁring, while electrochemical methods directly measure adeno-
sine release. Thus, the twomethods are complementary. Electrophysiol-
ogy measurements are on the millisecond time scale and were used to
demonstrate that adenosine acted at A1 receptors on a 1–2 second
time scale [46]. FSCV has conﬁrmed that adenosine release can last
only a few seconds [20] and showed rapid signaling of adenosine in
the brain. FSCV and electrophysiology studies have been combined at
the samemicroelectrode to measure dopamine [47] and similar studies
could be performed in the future to monitor the amount of adenosine
release and its effect on neuronal ﬁring.
3.3. Comparison of FSCV and Adenosine Biosensors
Another method for detecting adenosine is using amperometric
biosensors, which were developed by the Dale group [16]. Adenosine
biosensors directly measure adenosine at platinum electrodes coated
with enzymes that metabolize adenosine to hydrogen peroxide, which
is detected amperometrically at +0.5 V [48]. Adenosine is broken
down to inosine, then to hypoxanthine, then to xanthine, urate, andhydrogen peroxide via adenosine deaminase, purine nucleoside phos-
phorylase, and xanthine oxidase, respectively (Fig. 2A) [49]. Although
the biosensors are held at +0.5 V, the multiple polymer layers may
act as a barrier to prevent electroactive species from oxidizing [48],
while still allowing for detection of H2O2 without slowing response
time [49]. An identical null sensor which contains no adenosine deami-
nase is placed next to the biosensors to distinguish adenosine from any
interferents, particularly downstream metabolites. Subtracting out the
null sensor signal from the adenosine biosensor signal gives a speciﬁc
response for adenosine. The limit of detection for adenosine biosensors
is 12 nM and the rise time is about 2 s, which allows measurements of
adenosine release on the second time scale [48]. Fig. 2 shows evoked
adenosine release measured by biosensors. Adenosine release was
decreased by EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) hydro-
chloride, which inhibits adenosine deaminase (Fig. 2B); tetrodotoxin,
a blocker of action potentials (Fig. 2C); and removal of Ca2+ (Fig. 2D),
which blocks activity dependent release [50].
Biosensors have been used to examine the mechanism and function
of adenosine release, particularly in brain slices. In hippocampal slices,
5–10 min of hypoxia gradually increased adenosine over the ischemic
event [17]. Similarly, adenosine released during hypoxia was activity
dependent and not a downstream breakdown product of ATP [50,51].
Enzyme biosensors were also used to measure electrically stimulated
[52] and glutamate-induced adenosine release [53]. These studies
revealed that adenosine was released on a time scale of seconds to mi-
nutes following oxygen deprivation, electrical stimulation, or glutamate
application.
FSCV and amperometric biosensors are both electrochemical tech-
niques that measure adenosine directly. The limit of detection for aden-
osine at carbon-ﬁber microelectrodes is comparable to biosensors [48],
in the 15 nM range. FSCV at carbon-ﬁber microelectrodes has better
temporal resolution than biosensors, with rise times for FSCV being
only a few hundred milliseconds. Typically, adenosine biosensors are
platinum electrodes with diameters of 25 and 50 μm while carbon-
ﬁber microelectrodes are only 7 μm. Smaller electrodes cause less tissue
damage [54]. Adenosine releasemeasuredwith FSCV lasts only a couple
of secondswhile the releasemeasuredwith biosensors is usually longer,
on the order of a minute. Biosensors require a null sensor to screen out
metabolites, while metabolites such as inosine are electrochemically in-
active at carbon-ﬁber electrodes using FSCV [19]. However, biosensors
are able to measure basal changes in adenosine over a minute to hour
time scale, while FSCV cannot observe basal shifts because the signal
is background subtracted. With both techniques, evoked adenosine re-
lease is activity dependent on the rapid time scale [23,50]. Biosensors
for ATP have also been developed and can be used to distinguish aden-
osine and ATP signals [55].
3.4. Advantages and Disadvantages of FSCV
There are several advantages of FSCV for detection of adenosine. The
high sensitivity for adenosine allows measurements in the physiologi-
cally relevant range of receptor afﬁnities [56]. Adenosine is directly
detected, as opposed to measuring downstream effects, which is
beneﬁcial for determining mechanisms of release that may account for
adenosine signaling [57]. Another beneﬁt of FSCV with carbon-ﬁber
Fig. 2. Biosensor detection of adenosine. Left: A) Schematic of adenosine biosensor. The platinum electrode is coated with a permselective layer to prevent fouling and an enzymatic layer
that breaks down adenosine to hydrogen peroxide. Right: Evoked adenosine release in brain slices. B) EHNA, an adenosine deaminase inhibitor, lowers evoked adenosine release.
C) Tetrodotoxin (TTX), which inhibits action potentials, completely eliminates stimulated adenosine release. D) Ca2+ free buffer abolishes evoked adenosine release.
Data adapted with permission from Dale [49,50] and Springer Science and Business Media.
12 s
Fig. 3. Electrically stimulated adenosine in slices using FSCV. The appliedwaveform is shown
above the color plot. Electrically stimulated adenosine and dopamine are shown on the
false color plot in yellow circles. The dopamine and adenosine are cleared within 2 and
5 s of stimulation, respectively. A diagram of the location of electrode implantation in
the caudate–putamen is shown to the right.
Figure reprinted from [23] Copyright 2010 American Chemical Society.
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invasive than microdialysis probes of 250–500 μm [58]. Carbon-ﬁber
microelectrodes are also cheap and easy to make, as opposed to biosen-
sors which are usually purchased from a commercial source and are
more expensive.
The biggest advantage of FSCV is the time resolution of themeasure-
ments, 100 ms, which is the fastest method for measuring adenosine.
Adenine nucleotides undergo conversion to adenosine within 200 ms,
suggesting a need to detect adenosine on a fast time scale [59]. Biosen-
sors take around 2 s to respond to a change in adenosine and thus are
not fast enough to characterize many of the spontaneous adenosine
transient signals that last only 3 s on average [29]. The consequence of
fast scanning is a large background current, so local changes in concen-
tration are typically only measured over a 90 second window due to
background subtraction [60]. Using analog background subtraction
with principal component analysis, changes in dopamine concentra-
tions have been quantiﬁed over a 30 minute period [26], however this
method has not been tested with adenosine. A disadvantage of FSCV is
that it cannot measure basal concentrations of adenosine because it
requires background subtraction. However, FSCV is the best method
for measuring rapid changes and when combined with pharmacology
can be a powerful tool to understand transient adenosine signaling.
4. Biological Studies of Adenosine With FSCV
4.1. Electrically-stimulated Adenosine Release
Using FSCV, stimulated adenosinewas characterized in anesthetized
animals [20] and brain slices [22]. Electrically-stimulated release was
ﬁrst characterized in vivo in the caudate–putamen after dopamine
neurons in the medial forebrain bundle were stimulated [20]. Both the
evoked dopamine release and adenosine release occurred immediately.
Fig. 3 shows a false color plot in brain slices of stimulated dopamine
release and adenosine release being cleared in 2 and 5 s, respectively
[23]. On average, the peak evoked adenosine was 0.94 μM and lasted
15 s, in vivo [20]. Pharmacological experiments demonstrated that
propentofylline, an inhibitor of adenosine transport, decreased stimu-
lated release while ABT 702, an adenosine kinase inhibitor, increased
evoked release. Stimulated adenosine release increased oxygen ﬂow
within 5 s at the electrode, demonstrating that adenosine can control
cerebral blood ﬂow on a rapid time scale. A1 receptors self-regulated
adenosine release [21]; the A1 agonist, CPA, decreased evokedadenosine while the A1 antagonist, DPCPX, increased adenosine release
rapidly.
FSCV was also used to characterize stimulated adenosine release
in brain slices. Two different pulse trains, low and high frequency,
were compared in rat striatal slices [23]. The high frequency stimula-
tions (5 pulses, 60 Hz) evoked more adenosine than the low frequency
stimulations (5 pulses, 10 Hz). Blocking nucleoside transporters did not
change evoked adenosine concentration so stimulated adenosine was
not released through equilibrative transporters. Stimulated adenosine
release varied in different brain regions [24], with higher levels evoked
in the caudate–putamen and nucleus accumbens compared to the
cortex and hippocampus. While basal levels also differ in distinctive re-
gions [61], there was little trend between evoked levels of adenosine
[24] and previously measured basal levels [62,63].
The mechanism of stimulated adenosine release was examined on a
rapid time scale. Evoked adenosine release was activity dependent be-
cause Ca2+ chelation or application of tetrodotoxin (TTX) almost
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likely due to exocytosis of adenosine, exocytosis of its precursor ATP,
or the downstream result of activity-dependent neurotransmitter
release [57]. NMDA and AMPA antagonists decreased the release of
adenosine in the caudate–putamen and nucleus accumbens, showing
the dependence of adenosine release on ionotropic glutamate receptors
[24]. The effect of blocking ATP metabolism varied by brain region.
AOPCP and ARL 67156, inhibitors of ATP metabolism, had no effect in
the caudate–putamen, but decreased adenosine in the nucleus accum-
bens, hippocampus, and cortex. Thus, there are at least twomechanisms
of stimulated adenosine release: breakdownof extracellular nucleotides
and downstream effects of ionotropic glutamate receptors, but these
mechanisms differ by brain region.
4.2. Adenosine Release During Deep Brain Stimulation Probe Implantation
FSCV is being pioneered for human clinical trials in order to monitor
neurotransmitters during deep brain stimulation (DBS) [64]. DBS is
used to treat tremors but a phenomenon known as the micro-
thalamotomy effect has been observed where simply implanting a
probe in the thalamus reduces tremors without applying an electrical
stimulation [65]. Release of adenosine during probe implantation was
hypothesized to be important for this effect. Using FSCV, the implantation
of a carbon-ﬁber electrode into the thalamus was shown to release
adenosine within seconds (Fig. 4) [66]. Adenosine release was also ob-
served concurrently with tremor arrest [67]. Thus, FSCV in clinical trialsFig. 4. Adenosine release by DBS probe implantation. A) False color plot of DBS electrode im-
plantation in the human patient. The black arrow denotes the insertion of the electrode
and the blue arrow shows the immediate release of adenosine. B) A cyclic voltammogram
of adenosine shows the characteristic primary and secondary oxidation of adenosine at
1.4 V and 1.0 V, respectively.
Figure adapted from Lee's group [67] Copyright Elsevier (2012).is a valuable technique for understanding the release of adenosine on a
rapid time scale during microelectrode implantation and DBS treatment.
4.3. Mechanically Stimulated Adenosine Release
Our laboratory characterized the effect of small mechanical stimula-
tions bymoving an electrode, or a pipette near an electrode, a small dis-
tance. Adenosine transiently increased aftermechanical stimulation and
was cleared within 20 s [39]. Mechanical release of adenosine was ob-
served in vivo and in brain slices and was not due to cell death or tissue
damage [39]. Mechanically-stimulated adenosine decreased following
the application of EDTA (to complex Ca2+) and TTX, showing that the
release was activity dependent. Blocking the nucleoside transporter
with NBTI did not diminish the signal, proving that the release was
not through transporters.Mechanically-stimulated releasewas partially
blocked by POM-1, which inhibits the breakdown of ATP, showing that
some of the release was from ATP metabolism. The rapid release of
adenosine following electrode implantation or brain damage could be
neuroprotective.
4.4. Spontaneous, Transient Adenosine Release
Spontaneous, transient adenosine release was discovered in spinal
cord slices of mice using FSCV [68]. The duration of adenosine release
was only 1.5 s and the average concentration was 0.53 μM. This rapid,
transient release could not have been detected with microdialysis or
biosensors, as only FSCV has sub-second temporal resolution. The fre-
quency of transient release was low, with events occurring once every
3 min and was signiﬁcantly reduced when Ca2+ was removed from
the buffer, suggesting activity dependent release of adenosine. Knock-
out mice lacking NT5E and CD73, enzymes that convert AMP to adeno-
sine, also had a lower frequency of transients. A third enzyme, tissue
non-speciﬁc alkaline phosphatase (TNAP), was later found to inhibit
the rapid conversion of applied AMP to adenosine in the double knock-
out mice with FSCV [69]. The results suggested that adenosine tran-
sients were formed from rapidly hydrolyzed AMP; however the
inhibition of TNAP has not been tested for spontaneous, transient aden-
osine release.
Spontaneous, transient adenosine release was also characterized
in vivo in anesthetized rats [29]. No stimulation was applied and adeno-
sine release was observed that lasted only 3 s. Fig. 5 shows a false color
plot of three transients that occurwithin 20 s of each other. FSCV has the
temporal resolution to detect three distinct adenosine events in this
short time frame. The average adenosine concentration was 0.17 μM
in the caudate–putamen and 0.19 μM in the prefrontal cortex, however
transients as large as 2.5 μM were observed. The release was random
and events occurred on average about once every 3 min. A1 receptors
modulated the frequency of transient adenosine release, but the mech-
anism of regulation has not been elucidated. Interestingly, comparing
the mice and rat studies, the characteristics of spontaneous transient
adenosine release were similar even though they were measured in
two different rodent species and in two different regions [29,68]. This
suggests that spontaneous, transient adenosine release is a conserved
signaling pathway across species and regions.
5. Future Challenges
5.1. Determining the Mechanism and Location of Release
The biggest ﬁnding from FSCV research on adenosine has been the
discovery of a mode of signaling that lasts only a few seconds. The
sub-second temporal resolution of FSCV was needed to understand
the temporal dynamics of rapid release. Electrically-stimulated release,
mechanically-stimulated release, and spontaneous, transient adenosine
release all occur on this rapid time scale. Transient adenosine release
can be regulated by A1 receptors and partially by ionotropic glutamate
Fig. 5. Spontaneous transient adenosine release with FSCV. A false color plot shows three
spontaneous release events of adenosine in a 20 second window. The concentration vs
time trace above the color plot shows the three discrete events of adenosine.
Figure adapted from Nguyen et al. [29].
Fig. 6. Transientmodulation of stimulated dopamine releasewith FSCV. (A) Cyclic voltammo-
grams for stimulated dopamine release initially (black line), 2 s after adenosine applica-
tion (red line), and 10 min after adenosine application (dashed line). (B) Stimulated
dopamine after application of adenosine over different times. Evoked dopamine signiﬁ-
cantly decreased if adenosine was applied 2 or 5 s before stimulation.
Figure adapted from Ross and Venton [77] with permission fromWiley Company.
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signaling role for adenosine but questions still persist.
One of the remaining questions is about the mechanism of adeno-
sine release that leads to this rapid signaling. Extensive research from
multiple groups has concluded that rapid adenosine release is activity
dependent and not released through nucleoside transporters [23,24,
39,57,68,70]. A key question is whether adenosine is directly released
or is a breakdown product of ATP. In some studies, a portion of the
rapid adenosine released is due to ATP metabolism, but in most studies
there is also a portion of adenosine that is not from ATP. Because there
are multiple enzymes that breakdown ATP [69,71] and some of the
inhibitors of these enzymes are inefﬁcient [72], it is difﬁcult to rule out
ATP as the sole source of adenosine. However, adenosine was recently
discovered in vesicles [14], so future work should examine the possibil-
ity of direct release of adenosine from exocytosis versus breakdown of
exocytotically released ATP.
The exact cells that release adenosine on this rapid time scale have
not been distinguished and identifying the cellsmight also aid in under-
standing the mechanism of release. ATP is released as a neuronal co-
transmitter with dopamine, serotonin, GABA, and glutamate [73] and
adenosine release could be due to metabolism of ATP from those
neurons. Using Ca2+ imaging techniques, adenosine release has been
identiﬁed from astrocytes [74] and adenosine can be cleared by glial
cells as well [75]. FSCV can be used to measure exocytosis directly
from single cells, so future studies could examine adenosine release
from neurons and astrocytes to better understand the mechanism and
location of adenosine release.
5.2. Understanding the Function of Rapid Adenosine Release
When a new signaling mode of a molecule is identiﬁed, it is impor-
tant to characterize the function of that signaling. Transient adenosine
likely acts locally, as the distance a molecule such as adenosine could
diffuse in a couple of seconds is only 10–20 μm [76]. Adenosine is
known to modulate neurotransmission in the brain and so an obvious
hypothesis is that transient adenosine regulates neurotransmission on
a rapid time scale. Recently, our laboratory identiﬁed that transientadenosine release rapidly modulated phasic dopamine release. When
adenosine was transiently applied less than 10 s before dopamine was
electrically evoked, the stimulated dopamine concentration was
reduced by 50% (Fig. 6) [77]. This inhibitory effect was mediated by A1
receptors and only occurred while adenosine was present in the
extracellular space. Thus, rapid adenosine is able to modulate neuro-
transmission in discrete locations. Adenosine also modulated oxygen
concentrations in the brain [20], suggesting that transient adenosine
release can locally modulate oxygen and blood ﬂow. Future studies
could explore the extent to which transient adenosine modulates
other neurotransmitters.
FSCV should be useful in the future for understanding the role of
rapid adenosine release in diseases. For example, during epileptic
events, adenosine decreased excitatory glutamate release and hyper-
polarized neurons, which is desirable during hyper-excitatory seizures
[78]. FSCVwas used to detect adenosine release during epilepsy and sei-
zures in pigs and was safe in human experiments [79]. Adenosine was
released prior to seizure termination and remained elevated following
the epileptic event, which conﬁrms the idea that adenosine is involved
in seizure expiration [80]. FSCV has rapid time resolution so it could
be used to monitor adenosine during the rapid onset of seizures. FSCV
could help distinguish whether adenosine release is constant during
all seizures and determine if adenosine is released before or after the
onset of seizures.
5.3. Final Conclusions
FSCV allows adenosine detection on a sub-second time scale and has
been used to uncover a rapidmode of adenosine signaling that lasts only
53M.D. Nguyen, B.J. Venton / Computational and Structural Biotechnology Journal 13 (2015) 47–54a few seconds. Transient adenosine release can be measured after elec-
trical or mechanical stimulations. It can also be observed spontaneously
in brain slices and in vivo, when no stimulation is applied. This transient
release modulates phasic dopamine and oxygen ﬂow, which indicates
that rapid adenosine release has a fast neuromodulatory role. Future
studieswill use FSCV in conjunctionwith pharmacology, electrophysiol-
ogy, and biosensors to discover more about the mechanism and func-
tion of this mode of rapid adenosine signaling.Acknowledgements
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